Laura Ann Robertson

Title: Laura Ann Robertson: Innovator in Cardiac Treatment

Introduction

Laura Ann Robertson is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of cardiology, particularly in the treatment of hypertrophic cardiomyopathy. Her innovative approaches have the potential to improve patient outcomes and enhance the quality of life for those affected by this condition.

Latest Patents

Laura holds a patent for "Methods for treating hypertrophic cardiomyopathy." This patent describes treatment methods that include the administration of a cardiac myosin inhibitor, specifically CK-3773274, also known as CK-274 or aficamten. The methods involve titrating the daily dose based on various components of an echocardiogram, allowing for personalized treatment plans. The daily dose may be adjusted—whether increased, maintained, decreased, or terminated—based on the echocardiogram results.

Career Highlights

Laura is currently employed at Cytokinetics, Inc., where she continues to develop innovative treatments for cardiac conditions. Her work is characterized by a commitment to advancing medical science and improving therapeutic options for patients.

Collaborations

Some of her notable coworkers include Fady Malik and Stuart Kupfer, who contribute to the collaborative environment at Cytokinetics, Inc. Their combined expertise fosters innovation and drives the development of new treatment methodologies.

Conclusion

Laura Ann Robertson's contributions to the field of cardiology through her patent and work at Cytokinetics, Inc. exemplify her dedication to improving patient care. Her innovative methods for treating hypertrophic cardiomyopathy highlight the importance of personalized medicine in modern healthcare.